HydrocephalusNCT07694518
Role of Endoscopic Third Ventriculostomy Imanagement of Hydrocephalus in Pediatric Age Group; Clinical and Surgical Outcome
A study testing Fenestration of the floor of the third ventricle, Endoscopic third ventriculostomy of the brain third ventricle and Endoscopic third ventriculostomy in people with Hydrocephalus, run by Sohag University at 1 site in Egypt.
Trial summary
Endoscopic third ventriculostomy in cases of hydrocephalus provide less invasive and safe technique than ventriculoperitoneal Shunt also decrease complications of ventriculoperitoneal Shunt Read more about this study
- Who is it for?
- Ages 6 months to 18 years
- Conditions the study is for
- Hydrocephalus
- What is being tested?
- Fenestration of the floor of the third ventricle, Endoscopic third ventriculostomy of the brain third ventricle and Endoscopic third ventriculostomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 12 Jul 2026to 24 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- cases hydrocephalus diagnosed by CT or MRI.in pediatric age group up to 18 years
- Both sex (males and females) will be included.
Who cannot join
- cases with hydrocephalus associated with csf infection or hemorrhage
- Previously operated VP shunt or ETV .
- Mult cystic hydrocephalus
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Sohag University
Sohag
Sohag University Sohag University, Master, 0934602963, Portal@med.sohag.edu.eg
About this study
Official title: Role of Endoscopic Third Ventriculostomy in Management of Hydrocephalus in Pediatric Age Group; Clinical and Surgical Outcome
Endoscopic third ventriculostomy in cases of hydrocephalus provide less invasive and safe technique than ventriculoperitoneal Shunt also decrease complications of ventriculoperitoneal Shunt
Read the detailed description
Endoscopic third ventriculostomy (ETV) is a minimally invasive neurosurgical procedure used to treat obstructive hydrocephalus in children. By creating an opening in the floor of the third ventricle, the surgeon establishes a new pathway for cerebrospinal fluid (CSF) to bypass the blockage and drain naturally, potentially eliminating the need for a traditional brain shunt.
- Conditions
- Hydrocephalus
- Being tested
- Fenestration of the floor of the third ventricle, Endoscopic third ventriculostomy of the brain third ventricle, Endoscopic third ventriculostomy
- Medical subject headings
- Hydrocephalus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fenestration of the floor of the third ventricleProcedure or surgery
Endoscopic third ventriculostomy of the third ventricle of the brain
Endoscopic third ventriculostomy of the brain third ventricleProcedure or surgery
Surgeons insert a rigid endoscope through a small burr hole in the skull into the ventricular system. They use a catheter or laser to puncture a tiny, precise opening in the floor of the third ventricle
Endoscopic third ventriculostomyProcedure or surgery
Surgeons insert a rigid endoscope through a small burr hole in the skull into the ventricular system. They use a catheter or laser to puncture a tiny, precise opening in the floor of the third ventricle
| Study group | Role | What they receive |
|---|---|---|
| Hydrocephalus in pediatric age group | Other | Endoscopic third ventriculostomy in cases with hydrocephalus in pediatric age group Receives: Procedure: Fenestration of the floor of the third ventricle; Procedure: Endoscopic third ventriculostomy of the brain third ventricle; Procedure: Endoscopic third ventriculostomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in manifestation according to ETVSS endoscopic third ventriculostomy success score with assement of level of consciousness degree of papiledema and severity of headache
ETVSS ETV success score is predictive tool used to estimate ETV success based on factors like age etiology previous shunt other pathologies The score is expressed as a number from 0 to 90 with assement of level of consciousness degree of papiledema and severity of headache Score 70 indicate an estimated 70 % chance of success
Measured: 6 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start12 Jul 2026 (estimated)
- Primary completion14 Aug 2026 (estimated)
- Study completion24 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HydrocephalusStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Ismael Marzouk, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07694518
- Sponsor's protocol ID
- ETV in pediatric age group
- Other IDs
- Soh-Med-26-6-17MS
- Status last verified
- Jul 2026
- First submitted
- 1 Jul 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Endoscopic Third Ventriculostomy in Management of Hydrocephalus in Pediatric Age Group; Clinical and Surgical Outcome
- ClinicalTrials.gov ID
- NCT07694518
- Acronym / sponsor ID
- ETV in pediatric age group
- Conditions
- Hydrocephalus
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 12 Jul 2026 (estimated)
- Primary completion
- 14 Aug 2026 (estimated)
- Study completion
- 24 Dec 2026 (estimated)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endoscopic third ventriculostomy in cases of hydrocephalus provide less invasive and safe technique than ventriculoperitoneal Shunt also decrease complications of ventriculoperitoneal Shunt
Detailed description
Endoscopic third ventriculostomy (ETV) is a minimally invasive neurosurgical procedure used to treat obstructive hydrocephalus in children. By creating an opening in the floor of the third ventricle, the surgeon establishes a new pathway for cerebrospinal fluid (CSF) to bypass the blockage and drain naturally, potentially eliminating the need for a traditional brain shunt.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hydrocephalus in pediatric age group | Other | Procedure: Fenestration of the floor of the third ventricle, Procedure: Endoscopic third ventriculostomy of the brain third ventricle, Procedure: Endoscopic third ventriculostomyEndoscopic third ventriculostomy in cases with hydrocephalus in pediatric age group |
Who may qualify
- Ages
- 6 months to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (2 listed)
- cases hydrocephalus diagnosed by CT or MRI.in pediatric age group up to 18 years
- Both sex (males and females) will be included.
Key exclusion criteria (3 listed)
- cases with hydrocephalus associated with csf infection or hemorrhage
- Previously operated VP shunt or ETV .
- Mult cystic hydrocephalus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fenestration of the floor of the third ventricleEndoscopic third ventriculostomy of the third ventricle of the brain | Procedure or surgery | Hydrocephalus in pediatric age group |
| Endoscopic third ventriculostomy of the brain third ventricleSurgeons insert a rigid endoscope through a small burr hole in the skull into the ventricular system. They use a catheter or laser to puncture a tiny, precise opening in the floor of the third ventricle | Procedure or surgery | Hydrocephalus in pediatric age group |
| Endoscopic third ventriculostomySurgeons insert a rigid endoscope through a small burr hole in the skull into the ventricular system. They use a catheter or laser to puncture a tiny, precise opening in the floor of the third ventricle | Procedure or surgery | Hydrocephalus in pediatric age group |
Primary outcome
Changes in manifestation according to ETVSS endoscopic third ventriculostomy success score with assement of level of consciousness degree of papiledema and severity of headache
Time frame: 6 month
ETVSS ETV success score is predictive tool used to estimate ETV success based on factors like age etiology previous shunt other pathologies The score is expressed as a number from 0 to 90 with assement of level of consciousness degree of papiledema and severity of headache Score 70 indicate an estimated 70 % chance of success
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
Related trials for Hydrocephalus
RecruitingPhase 2
CEUS Evaluation of Hydrocephalus in Neonates and Infants
Hydrocephalus in Infants, Hydrocephalus Acquired
RecruitingObservational study
CoMind Early Feasibility Study
Intracranial Pressure, Intracranial Pressure Changes
RecruitingObservational study
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Cysticercosis, Neurocysticercosis
RecruitingObservational study
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Active, not recruiting
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Hydrocephalus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fenestration of the floor of the third ventricle, Endoscopic third ventriculostomy of the brain third ventricle and Endoscopic third ventriculostomy in people with Hydrocephalus, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed Esmael Marzouk, Resident (201156294688 ext. 201004213207, ahmed.esmael@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in manifestation according to ETVSS endoscopic third ventriculostomy success score with assement of level of consciousness degree of papiledema and severity of headache (time frame: 6 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.